Eglonyl 50mg 30 capsules — Made in France — Free Delivery

A neuroleptic agent. Sulpiride is a selective dopamine d2/d3 receptor antagonist. in patients with psychosis with negative symptoms, sulpiride is effective at a dose of 150-600 mg / day; at this dose, sulpiride has practically no effect on positive symptoms. at a dose of 0.6-1.6 g / day improves the condition of patients with acute or chronic psychosis with positive symptoms. only very high doses of sulpiride have a sedative effect.

After i / m administration at a dose of 100 mg, the maximum concentration of the preparation in blood plasma (about 2.2 mg / l) is reached after 30 minutes. When administered orally, sulpiride is absorbed in the digestive tract within 4.5 hours, the maximum concentration of the preparation in the blood plasma ranges from 0.5-1.8 mg / l after taking a dose of 200 mg. Bioavailability of oral forms - 25-35% with wide individual fluctuations; The concentration of sulpiride in plasma is proportional to the dose. Sulpiride is rapidly distributed in body tissues, mainly in the kidneys and liver; a small amount penetrates the BBB. Less than 40% of the preparation binds to plasma proteins; the distribution ratio of erythrocytes and blood plasma is 1. The amount of the preparation that penetrates into breast milk is 1/1000 of the daily dose. Sulpiride is poorly metabolized in the body. The half-life is 7 hours; the volume of distribution in the equilibrium state is 0.94 l / kg (0.6–1.5 l / kg) of body weight. The total clearance is 126 ml / min. Sulpiride is excreted mainly by the kidneys by glomerular filtration.

Acute and chronic psychosis; neurotic, psychofunctional and psychoaffective disorders associated with somatic diseases.

Initial treatment is carried out in / m administration of the preparation, after which they switch to oral administration. with neurotic, psychofunctional and psychoaffective disorders associated with somatic conditions:

Adults - 100-200 mg / day.

Children over 6 years of age: 5 mg/kg of body weight per day (if necessary, this dose may be increased to 10 mg/kg).

In acute and chronic psychosis, the dose is set in accordance with the predominant symptoms: negative - 200-600 mg / day, positive - 800-1600 mg / day.

It is not recommended to prescribe eglonil for diagnosed or suspected pheochromocytoma, since during treatment with antidopamine preparations, including some benzamides, cases of severe hypertension have been described in individuals with pheochromocytoma, as well as in prolactin-dependent tumors (for example, pituitary prolactinoma and breast cancer).

Sedation, drowsiness, early dyskinesia (spasmodic torticollis, oculogeric crises, trismus, decreasing with the appointment of anticholinergic antiparkinsonian preparations), extrapyramidal symptoms, the severity of which is partially reduced with the appointment of anticholinergic antiparkinsonian preparations, tardive dyskinesia that develops with prolonged use of antipsychotics (anticholinergic antiparkinsonian preparations are ineffective and may worsen the patient's condition), postural hypotension, impotence, frigidity, amenorrhea, galactorrhea, gynecomastia, hyperprolactinemia, weight gain.

With the development of hyperthermia, sulpiride should be canceled. hyperthermia may be a manifestation of neuroleptic malignant syndrome (pallor, hyperthermia and autonomic dysfunction). this precaution is especially important when using the preparation in high doses.

Care should be taken when treating elderly patients who are more susceptible to the action of the preparation